Publicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (13)

2024

  1. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

    Nature Medicine, Vol. 30, Núm. 8, pp. 2199-2207

2023

  1. Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma

    Blood Advances, Vol. 7, Núm. 22, pp. 7141-7150

  2. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

    Journal of Clinical Oncology

2022

  1. Six-Year Results from RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

    Journal of Clinical Oncology

2021

  1. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 2, pp. 97-105

2020

  1. New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO)

    British Journal of Haematology, Vol. 188, Núm. 6, pp. 888-897

2019

  1. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    The Lancet, Vol. 393, Núm. 10168, pp. 229-240

2018

  1. Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: Results from the open-label, multicenter, phase II DAWN study

    Journal of Clinical Oncology, Vol. 36, Núm. 23, pp. 2405-2412

  2. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204

  3. Rituximab plus lenalidomide in advanced untreated follicular lymphoma

    New England Journal of Medicine, Vol. 379, Núm. 10, pp. 934-946

2016

  1. Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients

    Acta Haematologica, Vol. 136, Núm. 2, pp. 76-84

2007

  1. A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma

    Leukemia and Lymphoma, Vol. 48, Núm. 1, pp. 39-45

2003

  1. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: A feasibility study

    Haematologica, Vol. 88, Núm. 5, pp. 555-560